Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00092495
Status:
COMPLETED
Last Update Posted:
2015-01-13
First Post:
2004-09-22
Brief Title:
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents GardasilV501-016
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Study to Demonstrate Immunogenicity and Tolerability of Gardasil V501 Quadrivalent HPV Types 6 11 16 18 L1 Virus-Like Particle VLP Vaccine in Preadolescents and To Determine End-Expiry Specifications for the Vaccine
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of the study is to determine if an investigational vaccine Gardasil V501 with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004_083 | None | None | None |